Cargando…

Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response

Objectives. To evaluate infantile spasms in children with Down syndrome including assessment of efficacy of treatments, presence of treatment lag, and to identify risk factors that may predict the occurrence of infantile spasms in this population. Methods. Medical charts, electroencephalograms, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Dee, Knupp, Kelly, Benke, Tim, Wolter-Warmerdam, Kristine, Moran, Maura, Hickey, Fran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328947/
https://www.ncbi.nlm.nih.gov/pubmed/30671494
http://dx.doi.org/10.1177/2333794X18821939
_version_ 1783386738818809856
author Daniels, Dee
Knupp, Kelly
Benke, Tim
Wolter-Warmerdam, Kristine
Moran, Maura
Hickey, Fran
author_facet Daniels, Dee
Knupp, Kelly
Benke, Tim
Wolter-Warmerdam, Kristine
Moran, Maura
Hickey, Fran
author_sort Daniels, Dee
collection PubMed
description Objectives. To evaluate infantile spasms in children with Down syndrome including assessment of efficacy of treatments, presence of treatment lag, and to identify risk factors that may predict the occurrence of infantile spasms in this population. Methods. Medical charts, electroencephalograms, and brain magnetic resonance images were evaluated in 37 children treated for infantile spasms at a single institution from 2005 to 2015. Results. Mean age at diagnosis was 9.16 months, with an average 1.38-month lag from spasms onset to start of medication. Prevalence of heart defects and pulmonary hypertension were significantly higher in those with infantile spams compared with those without. Eighty-one percent receiving adrenocorticotropic hormone as initial treatment experienced remission within 2 weeks, 94.1% had remission at 3 months compared with 18.8% at 2 weeks and 35.3% at 3 months for other first-line treatments. Type of treatment was the only predictor of good outcome. Conclusions. Results stress the importance of early recognition and adrenocorticotropic hormone treatment for this seizure disorder in children with Down syndrome.
format Online
Article
Text
id pubmed-6328947
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-63289472019-01-22 Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response Daniels, Dee Knupp, Kelly Benke, Tim Wolter-Warmerdam, Kristine Moran, Maura Hickey, Fran Glob Pediatr Health Original Article Objectives. To evaluate infantile spasms in children with Down syndrome including assessment of efficacy of treatments, presence of treatment lag, and to identify risk factors that may predict the occurrence of infantile spasms in this population. Methods. Medical charts, electroencephalograms, and brain magnetic resonance images were evaluated in 37 children treated for infantile spasms at a single institution from 2005 to 2015. Results. Mean age at diagnosis was 9.16 months, with an average 1.38-month lag from spasms onset to start of medication. Prevalence of heart defects and pulmonary hypertension were significantly higher in those with infantile spams compared with those without. Eighty-one percent receiving adrenocorticotropic hormone as initial treatment experienced remission within 2 weeks, 94.1% had remission at 3 months compared with 18.8% at 2 weeks and 35.3% at 3 months for other first-line treatments. Type of treatment was the only predictor of good outcome. Conclusions. Results stress the importance of early recognition and adrenocorticotropic hormone treatment for this seizure disorder in children with Down syndrome. SAGE Publications 2019-01-09 /pmc/articles/PMC6328947/ /pubmed/30671494 http://dx.doi.org/10.1177/2333794X18821939 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Daniels, Dee
Knupp, Kelly
Benke, Tim
Wolter-Warmerdam, Kristine
Moran, Maura
Hickey, Fran
Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response
title Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response
title_full Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response
title_fullStr Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response
title_full_unstemmed Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response
title_short Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response
title_sort infantile spasms in children with down syndrome: identification and treatment response
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328947/
https://www.ncbi.nlm.nih.gov/pubmed/30671494
http://dx.doi.org/10.1177/2333794X18821939
work_keys_str_mv AT danielsdee infantilespasmsinchildrenwithdownsyndromeidentificationandtreatmentresponse
AT knuppkelly infantilespasmsinchildrenwithdownsyndromeidentificationandtreatmentresponse
AT benketim infantilespasmsinchildrenwithdownsyndromeidentificationandtreatmentresponse
AT wolterwarmerdamkristine infantilespasmsinchildrenwithdownsyndromeidentificationandtreatmentresponse
AT moranmaura infantilespasmsinchildrenwithdownsyndromeidentificationandtreatmentresponse
AT hickeyfran infantilespasmsinchildrenwithdownsyndromeidentificationandtreatmentresponse